Lingguizhugan Decoction Targets Intestinal Microbiota and Metabolites to Reduce Insulin Resistance in High-Fat Diet Rats

References

• Sonnenburg JL, Backhed F. Diet-microbiota interactions as moderators of human metabolism. Nature. 2016;535(7610):56–64.
   PubMed Web of Science ®Google Scholar
• Luo J, Huang L, Wang A, et al. Resistin-Induced Endoplasmic Reticulum Stress Contributes to the Impairment of Insulin Signaling in Endothelium. Front Pharmacol. 2018;9:1226.
   Web of Science ®Google Scholar
• Majchrzak M, Brzecka A, Daroszewski C, et al. Increased Pain Sensitivity in Obese Patients After Lung Cancer Surgery. Front Pharmacol. 2019;10:626.
   PubMed Web of Science ®Google Scholar
• Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract. 2019;157:107843.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Ferrannini E, Groop L, et al. Type 2 diabetes mellitus. Nat Rev Dis Primers. 2015;1:15019.
   PubMed Web of Science ®Google Scholar
• Martel J, Ojcius DM, Chang CJ, et al. Anti-obesogenic and antidiabetic effects of plants and mushrooms. Nat Rev Endocrinol. 2017;13(3):149–160.
   PubMed Web of Science ®Google Scholar
• Kerru N, Singh-Pillay A, Awolade P, Singh P. Current anti-diabetic agents and their molecular targets: a review. Eur J Med Chem. 2018;152:436–488.
   PubMed Web of Science ®Google Scholar
• Wu Q, Wu S, Cheng Y, et al. Sargassum fusiforme fucoidan modifies gut microbiota and intestinal metabolites during alleviation of hyperglycemia in type 2 diabetic mice. Food Funct. 2021;12(8):3572.
   Web of Science ®Google Scholar
• Zhang H, Ta N, Chen P, Wang H. Erchen Decoction and Linguizhugan Decoction Ameliorate Hepatic Insulin Resistance by Inhibiting IRS-1Ser307 Phosphorylation In Vivo and In Vitro. Evid-Based Compl Alt. 2017;2017:1–11.
   Web of Science ®Google Scholar
• Guo Y, Li J, Wang Y, et al. Yinchen Linggui Zhugan Decoction Ameliorates Nonalcoholic Fatty Liver Disease in Rats by Regulating the Nrf2/ARE Signaling Pathway. Evid-Based Compl Alt. 2017;2017:1–11.
   Web of Science ®Google Scholar
• Zhang H, Ta N, Chen P, Wang H. Erchen Decoction and Linguizhugan Decoction Ameliorate Hepatic Insulin Resistance by Inhibiting IRS-1Ser307 Phosphorylation In Vivo and In Vitro. Evid Based Complement Alternat Med. 2017;2017:1589871.
   Web of Science ®Google Scholar
• Yang L, Lin W, Nugent CA, et al. Lingguizhugan Decoction Protects against High-Fat-Diet-Induced Nonalcoholic Fatty Liver Disease by Alleviating Oxidative Stress and Activating Cholesterol Secretion. Int J Genomics. 2017;2017:2790864.
   Web of Science ®Google Scholar
• Perry RJ, Samuel VT, Petersen KF, Shulman GI. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature. 2014;510(7503):84–91.
   PubMed Web of Science ®Google Scholar
• Quinn RA, Melnik AV, Vrbanac A, et al. Global chemical effects of the microbiome include new bile-acid conjugations. Nature. 2020;579(7797):123–129.
   PubMed Web of Science ®Google Scholar
• Chaudhari SN, Luo JN, Harris DA, et al. A microbial metabolite remodels the gut-liver axis following bariatric surgery. Cell Host Microbe. 2021;29(3):408–424.
   Web of Science ®Google Scholar
• Liu TC, Kern JT, Jain U, et al. Western diet induces Paneth cell defects through microbiome alterations and farnesoid X receptor and type I interferon activation. Cell Host Microbe. 2021;29(6):988–1001.
   Web of Science ®Google Scholar
• Larsen N, Vogensen FK, van den Berg FW, et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One. 2010;5(2):e9085.
   PubMed Web of Science ®Google Scholar
• Rahman K, Desai C, Iyer SS, et al. Loss of Junctional Adhesion Molecule A Promotes Severe Steatohepatitis in Mice on a Diet High in Saturated Fat, Fructose, and Cholesterol. Gastroenterology. 2016;151(4):733–746.
   PubMed Web of Science ®Google Scholar
• Liu MT, Huang YJ, Zhang TY, Tan LB, Lu XF, Qin J. Lingguizhugan decoction attenuates diet-induced obesity and hepatosteatosis via gut microbiota. World J Gastroenterol. 2019;25(27):3590–3606.
   PubMed Web of Science ®Google Scholar
• Zhao L, Lou H, Peng Y, Chen S, Zhang Y, Li X. Comprehensive relationships between gut microbiome and faecal metabolome in individuals with type 2 diabetes and its complications. Endocrine. 2019;66(3):526–537.
   Web of Science ®Google Scholar
• Lai M, Liu Y, Ronnett GV, et al. Amino acid and lipid metabolism in post-gestational diabetes and progression to type 2 diabetes: a metabolic profiling study. Plos Med. 2020;17(5):e1003112.
   PubMed Web of Science ®Google Scholar
• Li D, Cui Y, Wang X, Liu F, Li X. Apple Polyphenol Extract Improves High-Fat Diet-Induced Hepatic Steatosis by Regulating Bile Acid Synthesis and Gut Microbiota in C57BL/6 Male Mice. J Agric Food Chem. 2021;69(24):6829–6841.
   Web of Science ®Google Scholar
• Dang Y, Hao S, Zhou W, Zhang L, Ji G. The traditional Chinese formulae Ling-gui-zhu-gan decoction alleviated non-alcoholic fatty liver disease via inhibiting PPP1R3C mediated molecules. BMC Complement Altern Med. 2019;19(1):8.
   Web of Science ®Google Scholar
• Huang L, Duan C, Xia X, et al. Commensal microbe-derived propionic acid mediates juvenile social isolation-induced social deficits and anxiety-like behaviors. Brain Res Bull. 2021;166:161–171.
   PubMed Web of Science ®Google Scholar
• Shen DY, Kuo PC, Huang SC, et al. Constituents from the leaves of Clausena lansium and their anti-inflammatory activity. J Nat Med. 2017;71(1):96–104.
   PubMed Web of Science ®Google Scholar
• Yuan J, Peng G, Xiao G, et al. Xanthohumol suppresses glioblastoma via modulation of Hexokinase 2 -mediated glycolysis. J Cancer. 2020;11(14):4047–4058.
   PubMed Web of Science ®Google Scholar
• Tay KC, Tan LT, Chan CK, et al. Formononetin: a Review of Its Anticancer Potentials and Mechanisms. Front Pharmacol. 2019;10:820.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhou W, Zhan L, et al. Fecal microbiota transplantation alters the susceptibility of obese rats to type 2 diabetes mellitus. Aging. 2020;12(17):17480–17502.
   PubMedGoogle Scholar
• Wu J, Wang K, Wang X, Pang Y, Jiang C. The role of the gut microbiome and its metabolites in metabolic diseases. Protein Cell. 2021;12(5):360–373.
   PubMed Web of Science ®Google Scholar
• Hernandez-Ceballos W, Cordova-Gallardo J, Mendez-Sanchez N. Gut Microbiota in Metabolic-associated Fatty Liver Disease and in Other Chronic Metabolic Diseases. J Clin Transl Hepatol. 2021;9(2):227–238.
   Web of Science ®Google Scholar
• Mocanu V, Zhang Z, Deehan EC, et al. Fecal microbial transplantation and fiber supplementation in patients with severe obesity and metabolic syndrome: a randomized double-blind, placebo-controlled Phase 2 trial. Nat Med. 2021;27(7):1272–1279.
   Web of Science ®Google Scholar
• Shin NR, Lee JC, Lee HY, et al. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut. 2014;63(5):727–735.
   PubMed Web of Science ®Google Scholar
• Yoon HS, Cho CH, Yun MS, et al. Akkermansia muciniphila secretes a glucagon-like peptide-1-inducing protein that improves glucose homeostasis and ameliorates metabolic disease in mice. Nat Microbiol. 2021;6(5):563–573.
   PubMed Web of Science ®Google Scholar
• Rao Y, Kuang Z, Li C, et al. Gut Akkermansia muciniphila ameliorates metabolic dysfunction-associated fatty liver disease by regulating the metabolism of L-aspartate via gut-liver axis. Gut Microbes. 2021;13(1):1–19.
   PubMed Web of Science ®Google Scholar
• Jin Z, Sun Y, Yang T, et al. Nanocapsule-mediated sustained H2 release in the gut ameliorates metabolic dysfunction-associated fatty liver disease. Biomaterials. 2021;276:121030.
   Web of Science ®Google Scholar
• Wu Q, Liang X, Wang K, et al. Intestinal hypoxia-inducible factor 2alpha regulates lactate levels to shape the gut microbiome and alter thermogenesis. Cell Metab. 2021;33(10):1988–2003.
   Web of Science ®Google Scholar
• Sanna S, van Zuydam NR, Mahajan A, et al. Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases. Nat Genet. 2019;51(4):600–605.
   PubMed Web of Science ®Google Scholar
• Nagao-Kitamoto H, Leslie JL, Kitamoto S, et al. Interleukin-22-mediated host glycosylation prevents Clostridioides difficile infection by modulating the metabolic activity of the gut microbiota. Nat Med. 2020;26(4):608–617.
   PubMed Web of Science ®Google Scholar
• Ma Q, Li Y, Wang J, et al. Investigation of gut microbiome changes in type 1 diabetic mellitus rats based on high-throughput sequencing. Biomed Pharmacother. 2020;124:109873.
   PubMed Web of Science ®Google Scholar
• Li R, Huang X, Liang X, Su M, Lai KP, Chen J. Integrated omics analysis reveals the alteration of gut microbe-metabolites in obese adults. Brief Bioinform. 2021;22(3):548.
   Web of Science ®Google Scholar
• Zhuang P, Li H, Jia W, et al. Eicosapentaenoic and docosahexaenoic acids attenuate hyperglycemia through the microbiome-gut-organs axis in db/db mice. Microbiome. 2021;9(1):185.
   PubMed Web of Science ®Google Scholar
• Lu J, Wang S, Li M, et al. Association of Serum Bile Acids Profile and Pathway Dysregulation With the Risk of Developing Diabetes Among Normoglycemic Chinese Adults: findings From the 4C Study. Diabetes Care. 2021;44(2):499–510.
   Web of Science ®Google Scholar
• Zhuang P, Shou Q, Lu Y, et al. Arachidonic acid sex-dependently affects obesity through linking gut microbiota-driven inflammation to hypothalamus-adipose-liver axis. Biochim Biophys Acta Mol Basis Dis. 2017;1863(11):2715–2726.
   PubMed Web of Science ®Google Scholar
• Zhou M, Shao J, Wu CY, et al. Targeting BCAA Catabolism to Treat Obesity-Associated Insulin Resistance. Diabetes. 2019;68(9):1730–1746.
   PubMed Web of Science ®Google Scholar
• Li D, Feng Y, Tian M, Ji J, Hu X, Chen F. Gut microbiota-derived inosine from dietary barley leaf supplementation attenuates colitis through PPARgamma signaling activation. Microbiome. 2021;9(1):83.
   Web of Science ®Google Scholar
• Zhang Y, Bobe G, Miranda CL, et al. Tetrahydroxanthohumol, a xanthohumol derivative, attenuates high-fat diet-induced hepatic steatosis by antagonizing PPARgamma. Elife. 2021;10.
   Web of Science ®Google Scholar
• Xu X, Gao Z, Yang F, et al. Antidiabetic Effects of Gegen Qinlian Decoction via the Gut Microbiota Are Attributable to Its Key Ingredient Berberine. Genomics Proteomics Bioinformatics. 2020;18(6):721–736.
   PubMed Web of Science ®Google Scholar
• Liu Q, Zhang J, Han X, et al. Huiyang Shengji decoction promotes wound healing in diabetic mice by activating the EGFR/PI3K/ATK pathway. Chin Med. 2021;16(1):111.
   Web of Science ®Google Scholar
• McDonnell C, Leanez S, Pol O. The Inhibitory Effects of Cobalt Protoporphyrin IX and Cannabinoid 2 Receptor Agonists in Type 2 Diabetic Mice. Int J Mol Sci. 2017;18(11):87.
   Web of Science ®Google Scholar
• Rao Y, Kuang Z, Li C, et al. Gut Akkermansia muciniphila ameliorates metabolic dysfunction-associated fatty liver disease by regulating the metabolism of L-aspartate via gut-liver axis. Gut Microbes. 2021;13(1):1927619–1927633.
   Web of Science ®Google Scholar
• Hamada Y, Goto M, Nishimura G, et al. The alpha-glucosidase inhibitor miglitol increases hepatic CYP7A1 activity in association with altered short-chain fatty acid production in the gut of obese diabetic mice. Metabol Open. 2020;5:100024.
   Google Scholar
• Castellanos-Jankiewicz A, Guzman-Quevedo O, Fenelon VS, et al. Hypothalamic bile acid-TGR5 signaling protects from obesity. Cell Metab. 2021;33(7):1483–1492.
   PubMed Web of Science ®Google Scholar
• Guo J, Han X, Tan H, Huang W, You Y, Zhan J. Blueberry Extract Improves Obesity through Regulation of the Gut Microbiota and Bile Acids via Pathways Involving FXR and TGR5. iScience. 2019;19:676–690.
   PubMed Web of Science ®Google Scholar